CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study Article

sustainable development goals

publication date

  • March 27, 2025

webpage

published in

keywords

  • Adalimumab
  • Biosimilar
  • CT-P17
  • Interchangeability
  • Psoriasis
  • Switching
  • TNF
  • Tumor necrosis factor inhibitor
  • Yuflyma (R)